Nicox S.A.
COX | XPAR
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Developing innovative ocular solutions Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health. We plan to keep the maximum of options open for the company by maintaining rights to our novel therapeutics for eye diseases in key territories, such as the U.S. and Europe, as we create value by advancing their development, maintaining the potential for direct marketing, licensing for certain territories and growth through strategic transactions. We are focused on the discovery, development and commercialization of novel ophthalmic therapeutics for eye diseases.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-14 07:30 |
Earnings Release
Nicox annonce les résultats de l’étude exploratoire de phase 3b Whistler dans l…
|
French | 199.5 KB | |
| 2025-05-14 07:30 |
Earnings Release
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
|
English | 184.4 KB | |
| 2025-04-30 07:30 |
Earnings Release
Nicox Provides Full Year 2024 Financial Results
|
English | 181.9 KB | |
| 2025-04-30 07:30 |
Earnings Release
Nicox : Résultats financiers de l’année 2024
|
French | 180.4 KB | |
| 2025-03-19 07:30 |
Inside Information Statement
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler…
|
English | 218.6 KB | |
| 2025-03-19 07:30 |
Regulatory News Service
Nicoxannonce que la visite finale du dernier patient a été effectuée dans l’étu…
|
French | 237.5 KB | |
| 2025-03-06 07:30 |
Capital/Financing Update
Nicox prolonge l’horizon de sa trésorerie jusqu’au quatrième trimestre 2025
|
French | 297.6 KB | |
| 2025-03-06 07:30 |
Capital/Financing Update
Nicox Extends Cash Runway into Q4 2025
|
English | 239.3 KB | |
| 2025-03-03 07:30 |
Earnings Release
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Deve…
|
English | 232.7 KB | |
| 2025-03-03 07:30 |
Inside Information Statement
Nicox présente une nouvelle analyse de l'étude NCX 470 Mont Blanc et fournit un…
|
French | 265.2 KB | |
| 2025-01-22 07:30 |
Regulatory News Service
Nicox confirme son éligibilité au PEA-PME
|
French | 215.6 KB | |
| 2025-01-21 07:30 |
Earnings Release
Nicox : Point d’activité et résumé financier du quatrième trimestre 2024
|
French | 256.3 KB | |
| 2025-01-21 07:30 |
Earnings Release
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
|
English | 231.4 KB | |
| 2024-12-04 07:30 |
Regulatory News Service
Nicox annonce la première vente commerciale de ZERVIATE en Chine par son parten…
|
French | 244.9 KB | |
| 2024-12-04 07:30 |
Regulatory News Service
Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumensio…
|
English | 225.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Antibiotice S.A. | Romania | ATB | |
|
Aran Research & Development (1982) Ltd. | Israel | ARAN | |
|
Asarina Pharma AB | Sweden | ASAP |